[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624696":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":44,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Allergy Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Grass Allergic adults",null,"Adult patients aged ≥ 18 for whom pre-seasonal subcutaneous allergen immunotherapy (AIT) with Grassmuno ® is indicated for the treatment of IgE-mediated moderate to severe allergic rhinitis and\u002For rhinoconjunctivitis with no asthma or with well-controlled asthma elicited by grass pollen allergy",[13],"Drug: Grassmuno®",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Grassmuno®","SCIT for grass pollen allergy, observational study",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Ralph Mösges, Univ. Prof. Dr. med. Dipl.-Ing","CONTACT","+49 172 2056 230","Ralph.Moesges@Uni-Koeln.de",[27],{"facility":28,"status":29,"city":30,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Dr. Kasche","RECRUITING","Hamburg","Germany","DE",{"type":34,"coordinates":35},"Point",[36,37],9.99302,53.55073,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":10,"phoneExt":10,"email":10},"Daniela Kasche, Dr. med.",{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[45,48],{"name":46,"class":47},"Bencard Allergie GmbH","OTHER",{"name":49,"class":50},"ClinCompetence Cologne GmbH","UNKNOWN","100624696","grass-grass-mata-mpl-real-world-assessment-study-100624696",false,"NCT07412990","GRASS (Grass MATA MPL Real-world Assessment Study)","Eine Prospektive, Offene, Multizentrische, Nicht-interventionelle Studie Zur Erhebung Von Daten Zur Anwendung Von Grass MATA MPL 27 600 SU Und Compliance in Der täglichen Klinischen Praxis Bei Erwachsenen Gräserpollen- Allergikern","GRASS","At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who\n\n* are male and female patients\n* are 18 years of age or older\n* treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and\u002For rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen.\n* Patients will only be enrolled in the study after the treatment decision has been made\n\nExclusion Criteria:\n\nAt the physician's discretion, the study should not be offered to the following patients:\n\n* Patients who are not sufficiently proficient in or do not adequately understand the German language, as this would prevent adequate comprehension of study-relevant documents.\n* In addition, patients should not be included if any of the contraindications listed in the current Summary of Product Characteristics (SmPC) are present.","ALL","18 Years",{"count":62,"type":63},1000,"ESTIMATED","OBSERVATIONAL","Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.",[67],"Grass Pollen Allergy",[69],"Allergy, Grass-pollen, AIT, SCIT","2026-03-19",{"date":72,"type":73},"2026-03-20","ACTUAL",{"date":75,"type":73},"2026-03-11",{"date":77,"type":63},"2028-10-02",{"name":5,"class":6},1]